A B S T R A C T
Background. Lowe syndrome (LS) and Dent-2 disease (DD2) are disorders associated with mutations in the OCRL gene and characterized by progressive chronic kidney disease (CKD). Here, we aimed to investigate the long-term renal outcome and identify potential determinants of CKD and its progression in children with these tubulopathies. Methods. Retrospective analyses were conducted of clinical and genetic data in a cohort of 106 boys (LS: 88 and DD2: 18). For genotype-phenotype analysis, we grouped mutations according to their type and localization. To investigate progression of CKD we used survival analysis by Kaplan-Meier method using stage 3 CKD as the end-point. Results. Median estimated glomerular filtration rate (eGFR) was lower in the LS group compared with DD2 (58.8 versus 87.4 mL/min/1.73 m 2 , P < 0.01). CKD stage II-V was found in 82% of patients, of these 58% and 28% had moderate-to-severe CKD in LS and DD2, respectively. Three patients (3%), all with LS, developed stage 5 of CKD. Survival analysis showed that LS was also associated with a faster CKD progression than DD2 (P < 0.01). On multivariate analysis, eGFR was dependent only on age (b ¼ À0.46, P < 0.001). Localization, but not type of mutations, tended to correlate with eGFR. There was also no significant association between presence of nephrocalcinosis, hypercalciuria, proteinuria and number of adverse clinical events and CKD. Conclusions. CKD is commonly found in children with OCRL mutations. CKD progression was strongly related to the underlying diagnosis but did not associate with clinical parameters, such as nephrocalcinosis or proteinuria.
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I N T R O D U C T I O N
The oculocerebrorenal syndrome of Lowe (LS) (OMIM #309000) and its milder variant, Dent-2 disease (DD2) (OMIM #300555) are ultrarare X-linked disorders associated with mutations in OCRL, which encodes the enzyme inositol polyphosphate 5-phosphatase, OCRL1 [1, 2] . OCRL1 is involved in proximal tubular endocytosis and is also reported to play a role in the maturation of polarized epithelial cells and in cytokinesis and ciliogenesis [3, 4] . Despite being caused by mutations in the same gene, LS is characterized by multi-organ involvement with the triad of congenital cataracts, neurological abnormalities and a selective tubular dysfunction of variable extent, whilst the DD2 phenotype is restricted mainly to a proximal tubulopathy [5] [6] [7] . The life span of an affected individual with LS rarely exceeds 40 years and is mainly limited by progressive kidney failure [8] . Severity of chronic kidney disease (CKD) is variable and the factors determining this variability remain to be elucidated.
A genotype-phenotype effect has been observed in some disorders, but this has not been shown in LS and DD2 so far [9] .
However, there is a distinct distribution of mutations along the OCRL gene. In DD2, most mutations have been detected 5 0 of exon 8, whereas in classic LS, mutations concentrate in exons 8-24 [9] . Besides the extra-renal manifestations, there also appears to be a difference with regards to renal involvement in these two phenotypes in that the prevalence of renal failure is lower in patients with DD2 compared with LS (32 and 74%, respectively) [6] .
In the present study, we conducted retrospective analyses of genetic and clinical data in a large, well-characterized cohort of children with OCRL mutations. We aimed to compare the longterm renal outcome between the LS and DD2 groups and to investigate possible determinants of CKD progression, ranging from clinical factors, such as nephrocalcinosis, to a potential genotype effect.
M A T E R I A L S A N D M E T H O D S
This retrospective, multicentre study was designed to collect data obtained from paediatric patients (<19 years of age) with OCRL-related disorders. A spreadsheet with requested information was sent to clinicians. We requested the most recent data, including anthropometrical and biochemical parameters as well as clinical data obtained throughout the observation period [presence of hypertension, episodes of dehydration, stone obstruction, urinary tract infections, acute kidney injuries (AKI), numbers of contrast X-ray studies, presumed cause of death]. Additionally, the physicians were asked to provide details of treatments, including height and serum creatinine before and on growth hormone (GH) therapy. To determine longitudinally the rate of CKD progression, height and serum creatinine were obtained and individually an averaged estimated glomerular filtration rate (eGFR)/year was calculated.
Between September 2014 and December 2015, data on 107 patients (boys) with LS and DD2 were collected. Finally, due to lack of the height parameter in one patient, 106 children were included into the analysis. Eighty-eight cases (83%) presented with full oculo cerebro renal criteria, whereas the remaining patients, defined by clinicians as DD2, showed a milder phenotype of LS (n ¼ 6; 5.7%) or exhibited renal tubulopathy only (n ¼ 12; 11.3%). The patients originated from: Poland (n ¼ 27), Korea (n ¼ 24), Italy (n ¼ 16), the UK (n ¼ 15), Germany (n ¼ 10), Greece (n ¼ 6), Macedonia (n ¼ 3), and Kazakhstan, Malta, Serbia, Slovenia and Sweden (n ¼ 1, each).
eGFR was calculated using the original Schwartz method [10] , but with a revised k-value of 26 (when serum creatinine is in mmol/L) for patients with LS, as suggested previously [5] . The subject's severity of CKD was classified by strata defined by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) CKD staging system [11] , taking into account physiologically lower GFR in children <2 years [12] .
Urine analysis was performed on spot samples and calciuria, phosphaturia, glycosuria, aminoaciduria, untimed proteinuria, creatininuria and low-molecular weight proteinuria (LMWP) was determined by dipstick and/or formal local laboratory methods. Calciuria and proteinuria was also assessed by 24-h urine collection in some patients. Calcium excretion >4 mg/kg/ 24 h was classified as hypercalciuria, as well as an elevated calcium-to-creatinine ratio (Ca/Cr; mg/mg) in a spot urine sample with age-appropriate references [13] . Hyperphosphaturia was designated as the presence of a decreased tubular reabsorption of phosphate (<80%) or tubular maximum for phosphate reabsorption normalized to the ageappropriate lower limit of normal [14] . Hypoalbuminaemia was defined as serum albumin <35 g/L and hyperparathyroidism as serum intact parathyroid hormone >66 pg/mL. Plasma bicarbonates, phosphate and potassium values were assessed and acidosis, hypophosphataemia and hypokalaemia were defined when receiving supplementation or/and with decreased blood levels, i.e. for acidosis <22 mmol/L [15] , for hypophosphataemia [15] and for potassium <3.5 mmol/L. Fanconi syndrome was recognized when a constellation of proximal renal tubular abnormalities was present (i.e. LMWP, hypercalciuria, acidosis, glycosuria, aminoaciduria and hypophosphataemia).
Urinary protein-to-creatinine ratio (P/Cr; mg/mg) and daily protein excretion assessed in 24-h urine collection (mg/m 2 /h) were used to define the level of proteinuria. Patients were identified as having normal ratios (P/Cr < 0.2), significant proteinuria (P/Cr 0.2-2) or high grade proteinuria (P/Cr > 2). Daily proteinuria was graded into three groups: <4 mg/m 2 /h, 4-40 mg/m 2 /h and >40 mg/m 2 /h. In a few cases (n ¼ 13), only dipstick proteinuria was available and was graded as 1þ (closest to 30 mg/dL), 2þ (closest to 100 mg/dL), 3þ (closest to 300 mg/ dL) and 4þ (>2000 mg/dL). To integrate the different categories of proteinuria submitted by the various centres, we adopted a grading system (grade 0 -P/Cr ratio <0.2 or <4 mg/m 2 /h or <1þ; grade 1 -P/Cr ratio 0.2-2 or 4-40 mg/m 2 /h or 2þ; grade 2 -P/Cr ratio >2 or >40 mg/m 2 /h or 3þ/4þ) [16] . Nephrocalcinosis and nephrolithiasis were assessed from ultrasound and/or CT/X-ray reports. Height and body mass index (BMI) data in the European children were transformed into standard deviation scores (SDS) with reference to the World Health Organization growth charts (http://www.who. int/growthref/en). For children of Asian ethnicity, SDS data were reported directly by the treating physicians. Short stature was defined as height SDS less than À2.
For the genotype-phenotype analysis, we grouped mutations according to the following criteria: (i) the expected effect on the protein product (i.e. missense, unlikely to cause complete lack of protein production and truncated mutations, which comprise nonsense, frameshift, splice-site mutations and exonic deletions, assumed to produce no or a truncated protein product) [9] . (ii) The localization/position of mutations, i.e. mutations were analysed with respect to recognized functional OCRL1 domains [i.e. exons 2-5 for pleckstrin homology domain (PH); exons 9-15 for a central 5-phosphatase domain; exons 16-20 for ASPM-SPD2-Hydin (ASH); and exons 21-24 for Rho GTPase activating (RhoGAP) domain] [9] .
Statistical analysis
Data were presented as a mean (standard deviation) or as median (upper/lower quartiles) as appropriate for continuous variables and as absolute numbers and/or percentages for categorical variables. One-way ANOVA and unpaired t-test were used to analyse the data with normal distribution and homogeneous variances. The data that did not follow a Gaussian distribution were analysed with Mann-Whitney Utest or the Kruskal-Wallis test and the Dunn's post hoc test. The relationship between variables was analysed with the Spearman's rank correlation coefficient and by multivariate linear regression. Categorical data were analysed with the v 2 test or the Fisher-Freeman-Halton test. For the longitudinal analysis, a median of all available eGFR for all patients at each age (1-19 years) was calculated and was shown as trend lines over time (details are provided in Supplementary data, Figure S1 and Table S1 ). The age of eGFR decline (break-point) was calculated by means of piecewise linear regression. CKD progression was analysed by the Kaplan-Meier method in a univariate analysis. The end-point was the first measurement of eGFR <60 mL/ min/1.73 m 2 . Data were censored at the last available eGFR measurement, and differences between subgroups were assessed by the log-rank test. All results were considered significant at P < 0.05. Statistical calculations were performed using STATISTICA 10.0 PL (StatSoft Polska, Krak ow, Poland).
R E S U L T S
The characteristics of 106 children (all boys) from 97 families are displayed in Table 1 . The median age at last follow-up was 10 years (5.9; 16) and was similar between the LS and DD2 groups. The frequencies of abnormalities of tubular function reflected previous studies [5, 6, 17] and were as follows: LMWP (100%), hypercalciuria (80%), nephrocalcinosis (52%), nephrolithiasis (24%), metabolic acidosis (68%), hypophosphataemia (44%), hypokalaemia (20%), aminoaciduria (65%) and glycosuria (16%). An apparent complete renal Fanconi syndrome was identified in only six patients with LS (5.7%). Short stature was noted in 84% of patients when compared with a normal population. As expected, subjects with LS were shorter than those with DD2 (median height SDS: À3.98 versus À2.11, P < 0.001). Moreover, phosphate wasting and acidosis were observed more frequently in LS than in DD2 (see Table 1 ).
All patients presented with proteinuria. As LMWP was not reported/determined in all patients this parameter was not studied in detail. Twenty percent of children had significant proteinuria (grade 1 in 16/82 patients), and the rest of the patients had severe proteinuria (grade 2 in 66/82 patients). Urinary P/Cr ratio was commonly used for the assessment of proteinuria in our cohort (n ¼ 63). The median P/Cr ratio was 3.9 mg/mg (2.7; 7.1), and was greater in patients with LS compared with DD2 (P < 0.0001). Notably, P/Cr ratio did not correspond either to the severity of CKD or eGFR. Importantly, this parameter highly correlated with BMI SDS (r ¼ À0.58, P < 0.0001).
Clinical course and causes of death
Ten patients (9.4%) experienced at least one episode of urinary tract infection (9 patients had recurrent infections, i.e. >2 episodes), 18 patients (17%) had one episode of dehydration requiring hospitalization (7 patients had !2 episodes), 11 patients (10.4%) had AKI and 3 patients (2.8%) had urinary stone obstruction. These events were almost exclusively present SDS, standard deviation score; BMI, body max index; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; ESKD, end-stage kidney disease; TRP, tubular reabsorption of phosphate; TmP/GFR, tubular maximum for phosphate reabsorption; iPTH, intact parathyroid hormone; LMWP, low-molecular weight proteinuria; P/Cr ratio, protein-to-creatinine; Ca/Cr ratio, calcium-to-creatinine; ACE, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; GH, growth hormone; ns, not significant. in patients with LS, except two episodes of dehydration in one patient with DD2. Seventeen individuals (16%) underwent contrast X-ray studies. Four patients (3.7%) died in the analysed cohort (the genotypes of three patients are shown in Supplementary data, Table  S2 ). In one previously reported patient (ls13) [17] , death occurred at the age of 18 months and was related to pneumonia, while the other three patients died at later ages: one (ls25.2; 11.5 years) due to apnoea/deep acidosis, and the other two, including the patient ls25.4 (17-18 years) due to sudden death of unknown causes. Notably, the two patients (ls25.2 and ls25.4) were from the same family (cousins) and had the same complex genotype described in detail elsewhere [17] .
Chronic kidney disease
Median eGFR was lower in the LS group compared with DD2 (58.8 versus 87.4 mL/min/1.73 m 2 , P < 0.01). CKD stage 2-5 was found in the majority of patients (74%) when the entire age range was analysed, and was evident in 82% of patients when the analysis was restricted to those >2 years (n ¼ 97). Overall, nearly half of the patients (49%) had moderate (eGFR 30-59 mL/min/1.73 m 2 ) and 9.3% severe CKD (eGFR <30 mL/ min/1.73 m 2 ). Moderate-to-severe CKD was more common in LS compared with DD2 (58 versus 28%). End-stage kidney disease (ESKD) was found only in LS individuals. Two patients (ls66 and ls76), who developed ESKD at ages of 14 and 16 years, respectively, harboured mutations in exon 22 (p.Arg822* and p.Glu806Asp, respectively), while the third patient (ls25.4), with ESKD at the age of 17 years, had a complex mutation in exon 14/intron 14 (p.Arg486Serfs). Importantly, his cousin (ls25.3) with the same genotype had severe CKD (eGFR of 15.5 mL/ min/1.73 m 2 ) (Supplementary data, Table S2 ). In the univariate analysis (Table 2) , there was a significant relationship between eGFR and Ca/Cr ratio (r ¼ 0.32, P < 0.01) as well as between eGFR and age in the whole group (r ¼ À0.5, P < 0.0001; Figure 1 ). After the multivariate analysis, only age remained significantly correlated (b ¼ À0.46, P < 0.001). Both age and Ca/Cr corresponded also with CKD stages. The presence of nephrocalcinosis, hypercalciuria, proteinuria, the number of adverse clinical events (mentioned above) and contrast X-ray studies had no evident effect on renal function. Height SDS was highly correlated with bicarbonate levels (r ¼ 0.35, P < 0.0001) and the patients with uncorrected acidosis were significantly shorter than their counterparts without acidosis (height SDS: À4.08 versus À3.03, P < 0.0001).
In the longitudinal analysis, in children with LS eGFR linearly falls with age and a clear break-point of eGFR decline occurs at the age of 10 years, whereas in subjects with DD2 eGFR remained stable during childhood (Figure 2 and Supplementary data, Figure S1 ). Renal survival censored by Kaplan-Meier analysis showed that LS was also associated with a faster progression to stage 3 of CKD (P < 0.01; Figure 3A ). Table 1 summarizes participants' treatment characteristics. The analysis of therapy in our group showed variable treatments. Overall, acidosis was treated in 57% of patients with alkali therapy, yet 49.5% remained acidotic. A third (33%) of patients were hypophosphataemic, yet only 23% received phosphate supplementation. Similarly, 14.4% were hypokalaemic, and 13% received potassium supplementation. Overall, 34% of patients did not receive any treatment.
Treatment
Eleven patients (10.4%; nine patients with LS) had been treated with GH for a median time of 64 months (range 30-89), and all but one had experienced an increase in height. Mean height SDS increased from À4.08 6 1.30 to À3.20 6 1.36 (P < 0.001). Yet, eight patients were still short-statured. In DD2 patients who had a slight growth deficiency (height SDS À2.2 and À2.8), height on GH normalized. There was no apparent association with eGFR (59.7 6 34.8 versus 59.4 6 25.0 mL/ min/1.73 m 2 , before and after the therapy, respectively), although in one patient, a significant deterioration in eGFR was observed (97 versus 35 mL/min/1.73 m 2 ), which was in excess of the expected age-associated deterioration.
Analyses of OCRL mutations
Supplementary data, Table S2 shows a summary of the mutations and their predicted effects on OCRL1 protein. In our study cohort, 104 patients (98%) had a molecular diagnosis, eGFR, estimated glomerular filtration rate; SDS, standard deviation score; BMI, body max index; iPTH, intact parathyroid hormone; P/Cr ratio, protein-to-creatinine; Ca/Cr ratio, calcium-to-creatinine.
FIGURE 1:
A scatter plot of eGFR versus age in children with Dent-2 disease (squares) and Lowe syndrome (black dots) (r ¼ À0.5, P < 0.0001, for the entire group).
which was made at a median time of 2.6 years (0.8; 9.5) ( Table 1 ), yet a molecular result was not available for five patients. A total of 90 different mutations were found in the 99 mutation-positive patients. Two patients with classical features of LS and three patients with a clinical diagnosis of Dent disease had no detectable mutations in OCRL or CLCN5. We report 17 (19%) previously unreported mutations in 21 patients associated either with LS or DD2. The phenotypic features of patients harbouring novel mutations are presented in Table 3 . As evident in Table 4 , the mutations are diverse. More than twothirds of patients (66.6%) carry truncating mutations. As demonstrated in the genogram (Figure 4) , mutations are scattered throughout the gene, and mutations in LS locate between exons 8 and 24, whereas they affect exons 4-15 in DD2. We did not observe any OCRL mutation found in both LS and DD2.
Genotype-phenotype correlation
The median eGFR for carriers of a truncating mutation (n ¼ 66) and for a missense mutation (n ¼ 33) was 58.82 mL/min/ 1.73 m 2 (44; 82.44) and 68.4 mL/min/1.73 m 2 (54.5; 91), respectively (P ¼ 0.12). The mutations were also tested for the position along the gene with the patients separated into four groups, which refer to the respective OCRL1 domains (Figure 4) . The cross-sectional analysis showed a tendency for a decrease in eGFR along the gene (P < 0.05; Figure 5 ). There were no significant differences in median ages between the analysed mutational groups. Similar analyses were done by Kaplan-Meier method. Renal survival was not different between mutational types (P ¼ 0.24) and the mutations' localization (P ¼ 0.36; Figure 3B ).
Furthermore, we observed strong inter-familial variability of eGFR. For example, among four patients with the same genotype (c.2464C>T; p.Arg822*), only one (ls66) had ESKD (14.3 years), whereas two other patients of similar age (11 and 16 years) had CKD stage 2 and 3 respectively, and the third had normal eGFR (4.6 years). We also found evidence of significant intra-familial variation of eGFR as illustrated in one of the FIGURE 3: A comparison of chronic kidney disease (CKD) progression analysed by Kaplan-Meier survival with the end-point at stage 3 of CKD between children with Lowe syndrome and Dent-2 disease (P < 0.01) (A), and between patients carrying mutations with respect to the functional OCRL1 domains (B; P ¼ 0.36) (PH, pleckstrin homology; 5P, 5-phosphatase; ASH, ASPM-SPD2-Hydin; RhoGAP, Rho GTPase activating). families (ls25) with four affected boys, of whom two had severe CKD, while the other two had stage 2 of CKD at a comparable age.
D I S C U S S I O N
This study presents a comprehensive analysis of molecular defects, clinical phenotypes and treatments with respect to CKD. The most important finding from this analysis was that among OCRL patients, those diagnosed with LS have worse renal function than those with DD2 and a faster rate of CKD progression in LS. Whether this is related to genotype or to other as yet unidentified factors that explain the difference between developing LS or DD2 remains to be determined. However, mutations that affect exons at the 3 0 end of the gene that encode the RhoGAP domain appear to be associated with more severe CKD. As mutations of subjects with DD2 localize in exons 2-15, compared with exons 8-24 in LS patients [9] , mutation localization does appear to correlate with disease severity. However, we also observed a strong inter-and intrafamilial variability of eGFR in patients with the same mutation. Suboptimal medical treatment, which in fact was demonstrated in our study, might be a significant determinant of the variability. This clinical variation in renal function might also be explainable by the individual ability to compensate for the loss of OCRL1 function. It has been suggested that this occurs through INPP5B, an inositol 5-phosphatase, which shares nearly all functional domains with OCRL1 [18] . It is questionable, however, whether this mechanism does explain the Splice defect y/n N/A y/n y y n n y n 37 -ls6.2 e 17 Intron 23 c.2581þ1G>A
Splice defect y/n N/A y/n y y y n n n 34 -ls73 1. [15] and had an HCO3 À level >22 mmol/L. Importantly, we found a high proportion of patients with uncorrected acidosis, which corresponded with a high frequency of growth impairment and CKD. Potentially, part of the growth deficiency may result from acidosis. Indeed, in our study in the LS group height strongly correlated with actual acidosis. Yet, no relationship could be disclosed between height and eGFR.
The limitations of our study include its retrospective and multicentre nature, which is the reason for partially incomplete and non-uniform data acquisition. The relatively small number of patients with DD2 in comparison with LS, as well as restriction of the study to children, also limits the power of our study to demonstrate renal survival.
In summary, we confirmed the high prevalence of CKD in children with OCRL mutations and found a difference in clinical outcome with respect to progression of CKD associated with different OCRL phenotypes. We did not identify an association between CKD and nephrocalcinosis and proteinuria, suggesting that modifying these factors will have no impact on the longterm kidney function.
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Supplementary data are available online at http://ndt.oxfordjour nals.org.
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